Related Experiment Videos
[Primary and secondary prevention of coronary disease by statins]
1Service de Cardiologie, CHU Purpan, 31059 Toulouse.
Abstract:
In the context of the growing complexity of atherosclerosis, LDL-cholesterol has been gradually revealed to be the main aetiological agent. However, the first clinical trials were not convincing, as they failed to demonstrate a significant improvement of coronary mortality. So-called "regression" trials revealed the need to develop clinical trials in which the primary endpoint is coronary events and no longer intermediate criteria such as the course of coronary disease on coronary angiography. Lovastatin, simvastatin and pravastatin were shown to be effective in the prevention of relapses in coronary patients and in the prevention of coronary events in healthy subjects. In 1999, the prescription for coronary patients should almost always include a statin and the prescription in healthy subjects should include a statin when this subject presents a high risk of coronary events in the years to come.
Insights
Low-density lipoprotein cholesterol (LDL-C) is a key factor in atherosclerosis. Statins effectively prevent coronary events in patients and high-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Atherosclerosis is a complex disease where LDL-cholesterol is increasingly recognized as the primary etiological agent.
- Early clinical trials on LDL-cholesterol reduction did not convincingly demonstrate significant improvements in coronary mortality.
- The limitations of "regression" trials highlighted the necessity for clinical studies focusing on coronary events as the primary endpoint, rather than intermediate markers like coronary angiography findings.
Purpose:
- To evaluate the efficacy of statins in preventing coronary events.
- To establish the role of statins in managing atherosclerosis and reducing cardiovascular risk.
Summary:
- Lovastatin, simvastatin, and pravastatin have demonstrated effectiveness in preventing recurrent coronary events in patients with existing coronary artery disease.
- These statins are also effective in preventing initial coronary events in healthy individuals identified as high-risk for future cardiovascular disease.
- The findings support the widespread use of statins in clinical practice for both secondary and primary prevention of cardiovascular events.
Impact:
- Statins are now a cornerstone therapy for patients with coronary artery disease, significantly reducing the risk of recurrent events.
- In 1999, statin therapy is recommended for nearly all coronary patients and for high-risk healthy individuals to prevent future coronary events.
- This research has shaped current guidelines for lipid management and cardiovascular disease prevention, emphasizing the critical role of LDL-cholesterol lowering with statins.